Uncovering the clinical impact of kallikrein-related peptidase 5 (KLK5) mRNA expression in the colorectal adenoma-carcinoma sequence

摘要

Background: Kallikrein-related peptidases (KLKs) are a subgroup of serine proteases located on chromosome 19ql3.3. Most KLKs have been extensively studied as potential biomarkers for several carcinomas and other diseases. KLKS was originally identified from a keratino-cyte library, and its enzyme was purified from the stratum corneum of human skin. KLKS was shown to be differentially expressed in a variety of endocrine tumors, although it is not as yet examined widely in colorectal cancer (CRC). Methods: In this study, we quantitatively assessed the mRNA expression status of KLKS in 197 colorectal tissues from 133 patients (70 cancerous and their paired normal colonic mucosa for 64 of them, as well as 63 colorectal adenomas) by quantitative real-time PCR (qPCR) using TaqMan probes. Statistical analysis evaluated the results. Results: It was shown that KLK5 expression is reduced following the histologically non-cancerous-adenoma sequence (p< 0.001), whereas it is increased during the sequence adenoma-carcinoma (p< 0.001). Furthermore, KLKS positive expression is associated with positive nodal status (p = 0.022), advanced tumor stage (p = 0.038) and high histological grade (p = 0.033). Cox univariate analysis revealed that KLKS positive expression is associated with disease-free survival (DFS) (p = 0.028) and overall survival (OS) of patients (p = 0.048). Kaplan-Meyer survival models showed that patients with positive KLKS expression have lower DFS (p = 0.009) and OS (p = 0.019). Receiver operating characteristic (ROC) analysis demonstrated for first time that KLKS expression had significant discriminatory values between cancer and adenoma tissues (area under the curve [AUC] 0.77; 95% confidence interval [CI] = 0.69-0.85, p = 0.03). Conclusions: KLKS mRNA expression may be useful for the differentiation of CRC from colorectal adenoma and represents a potential unfavorable prognostic biomarker for CRC.